Alloimmunisation rate of patients on Daratumumab: A retrospective cohort study of patients in England.

Tom BullockAmie FosterBryony Clinkard

Published in: Transfusion medicine (Oxford, England) (2021)

Given the low rate of RBC alloimmunisation, consideration should be given to revising the pre-transfusion testing regimen in this cohort. This may improve testing costs, turn-around times and evidence-based patient care.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
cardiac surgery
living cells
fluorescent probe
sickle cell disease